Cellagen Technology LLC
 
작성일 : 16-02-15
[Cellagen Technology LLC] Disease Area, Renal Disease

 

Disease Area, Renal Disease

 

 

Product Name: CDDO (Bardoxolone) l anti-inflammatory (#C2336-5)

 

클릭하시면 닫힙니다.이미지 저장을 원하시면 마우스 오른쪽클릭후 '다른이름으로 저장'을 하세요

 

CDDO is a synthetic oleanane triterpenoid. It is 400,000x more potent than natural product oleanolic acid in

inhibiting cellular iNOS production when stimulated by IFN-gamma, TNF-alpha, and IL-1 [1]. The

mechanism of action of CDDO remain elusive, despite its broad biological activities, including proliferation

inhibition, apoptosis induction[2], and oxidative stress and inflammation suppression.

CDDO-methyl ester,an orally-available form of CDDO, is undergoing clinical development for the treatment of

advanced chronic kidney disease (CKD) in type 2 diabetes mellitus patients.

 

Details

Chemical Formula:

 

C31H41NO4

CAS No.:

 

218600-44-3

Molecular weight:

 

491.66

Purity:

> 98%

Appearance:

 

Brown

Chemical name:

 

2-cyano-3, 12-dioxo-oleana-1,9(11)-dien-28-oic acid

Solubility:

 

Up to 10 mM in DMSO

Synonyms:

 

CDDO, RTA-401, RTA401, Bardoxolone

Storage:

For longer shelf life, store solid powder or DMSO solution at -20oC

 

References

1. Sporn MB, et al. New synthetic triterpenoids: potent agents for prevention and treatment of tissue injury

   caused by inflammatory and oxidative stress. J Nat Prod. 2011; 74(3):537-45. Pubmed ID: 21309592

2. Suh N, et al. A novel synthetic oleanane triterpenoid, 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid, with

   potent differentiating, antiproliferative, and anti-inflammatory activity. Cancer Res. 1999; 59(2):336-41.

   Pubmed ID: 9927043

 

 

Product Name: FG-4592 (ASP1517) l HIF prolyl-hydroxylase hibitor (#C3445-10)

 

클릭하시면 닫힙니다.이미지 저장을 원하시면 마우스 오른쪽클릭후 '다른이름으로 저장'을 하세요

 

FG-4592 is an orally-available isoquinoline-based inhibitor of hypoxia-inducible factor (HIF) prolyl

hydroxylase for the treatment of anemia and patients with chronic kidney disease. [1] Phase 2 studies

indicate that oral administration of FG-4592 three times a week increased mean hemoglobin levels in the first

eight weeks, regardless of supplementation with IV or oral iron, or no iron supplementation. FG-4592 is novel

in that it allows integration of red blood cell production and efficient iron incorporation simultaneously. [1]  

Data from Phase 2 trials comparing with epoetin alpha indicate that treatment with FG-4592 alone results in a

sustained reduction of total plasma cholesterol levels by an average of 20%, while no reduction was seen

with epoetin alpha. [2, 3]

In December, 2012, Fibrogen and Astellas Pharma announced the initiation of a Phase 3 clinical development

program for the treatment of anemia associated with chronic kidney disease in patients not on dialysis and

on dialysis. [4]

 

Details

Chemical Formula:

 

C19H16N2O5

CAS No.:

 

808118-40-3

Molecular weight:

 

353.24

Purity:

> 98%

Appearance:

 

Yellow

Chemical name:

 

2-(4-hydroxy-1-methyl-7-phenoxyisoquinoline-3-carboxamido)acetic acid

Solubility:

 

Up to 100mM in DMSO

Synonyms:

 

FG-4592, FG4592, ASP1517

Storage:

 

For longer shelf life, store solid powder at 4oC desiccated, or DMSO solution

at -20oC

 

References

1. "Correction of anemia without IV iron supplementation in incident dialysis patients" Fibrogen press release,

   Nov. 5, 2012

2. "FG-4592 and epoetin alpha in Phase II anemia study", Datamonitor Research Store, Nov. 11, 1012.

3. "Hemoglobin correction and maintenance in end-stage renal patients" Fibrogen press release, Nov. 5, 2012

4. Fibrogen press release, Dec. 11, 2012 (Phase 3 announcement)

 

 

 

Ordering informations

    

Catalog No.

Product Name

Size

C2336-5

CDDO (Bardoxolone) l anti-inflammatory

5 mg, 25 mg & 100 mg

C3445-10

FG-4592 (ASP1517) l HIF prolyl-hydroxylase inhibitor

10 mg, 50 mg & 250 mg

 

 

▣ 관련 페이지 ; Cellangen Technology